Impact Therapeutics Inc

Impact Therapeutics Inc: IMPACT Therapeutics is a privately held clinical-stage biopharmaceutical company and dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. We have assembled a highly differentiated and de-risked pipeline highlighted with three most advanced compounds in targets with proof-of-concept validation and superior drug properties over competitors. With three compounds in clinical stage including PARP inhibitor in pivotal studies, we possess leading global DNA damage response (DDR) pipeline with the most synthetic lethality clinical compounds among biotech companies. Meanwhile, we are expanding drug discovery platform to other novel synthetic lethality targets. Financed by recognized venture capitals including Lilly Asia Ventures and led by experienced management team, IMPACT established fully functioned R&D and operation in China and US.

Senaparib (IMP4297) is a novel agent targeting PARP (poly-ADP ribose polymerase) developed by IMPACT. Early clinical data showed the potential to be the best-in-class PARP inhibitor with better safety profile and wider therapeutic window. These enable Senaparib more suitable for long-term therapies and combination therapies. IMPACT and Junshi Biosciences established a 50:50 joint venture that focuses on the development and commercialization of Senaparib in China. The JV is currently conducting a Phase II pivotal study and a Phase III study of Senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. Outside China, IMPACT alone is conducting a Phase I/II study of Senaparib and temozolomide combination therapy in solid tumors and small cell lung cancer treatment, as well as a Phase II study of Senaparib monotherapy in prostate cancer maintenance treatment.

IMP7068 is a novel Wee1 inhibitor discovered and developed by IMPACT Therapeutics, with worldwide intellectual property, part of in-house DDR franchise. Compared to other Wee1 inhibitor, IMP7068 has better selectivity, longer half-life, and higher drug exposure, all of which would potentially lead to superior therapeutic window in treating patients. IMPACT is conducting a global Phase I study of IMP7068 in multiple regions.

IMP9064 is a novel ATR inhibitor which also showed high potency and selectivity in preclinical studies. IMPACT has filed US IND and is planning for China IND.

Besides, IMPACT is developing multiple DDR agents including ATM, Chk1/2, DNA-PK and undisclosed novel synthetic lethality programs in different stages from clinical candidate to early discovery. IMPACT also has a novel hedgehog pathway inhibitor IMP5471, which received China IND approval recently, available for partnership discussion.
Sector/Industry:
Healthcare
Characteristics:
Based in...
Asia
Clinical Stage
Phase III
Disease Space
Oncology
Listing
Private
Website:
Address:
12F, New Bund Times Square
399 Haiyang West Road
Pudong District, Shanghai, 200126
China

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Jun Bao, PhD, CEO

Upcoming Company Event Participation